吉利德科学公司Remdesivir专利分析及启示

Analysis and Enlightenment of Gilead Sciences’Patents on Remdesivir

美国吉利德科学公司(Gilead Sciences,Inc.)在研药物瑞德西韦(Remdesivir)在针对美国首例新型冠状病毒肺炎(COVID-19)确诊病例的试验性治疗中迅速表现出临床症状缓解效果。吉利德公司旋即声明提供Remdesivir用于试验性治疗,以支持应对新型冠状病毒感染暴发。2020年4月29日,中美三个临床试验研究团队同时发布了不同的研究结论,再度引发全球热议。本文检索了吉利德科学公司Remdesivir专利,对其专利市场布局概况及主要技术内容进行了分析,重点研究了其中国专利保护情况。结果表明,吉利德科学公司相关专利技术保护严密、市场布局主动、运营潜力巨大,值得国内新药研发企业借鉴。

Remdesivir,a drug under investigation of Gilead Sciences Inc.in the United States,was used on the first confirmed patient’s experimental treatment of the US.for a compassionate use,showing a clinical symptom of relief.The Gilead immediately announced working closely with global health authorities to respond to the novel coronavirus(COVID-19)outbreak through the appropriate experimental use of the investigational compound Remdesivir.In this paper,the patent information on Remdesivir of Gilead is retrieved and analyzed.And the layout of the patent situation in China is dissect especially.It would be beneficial to guide the drug R&D of domestic innovative pharmaceutical companies.